CLAIMS

1. A compound of the Formula (I) or a pharmaceutically-acceptable adduct thereof



(I)

wherein:

R^1 is hydrogen, C_{1-3} alkyl or $-CH_2OMe$;

R^2 is pyridinyl, optionally substituted on 1 ring carbon atom by a substituent independently selected from the group consisting of C_{1-3} alkyl, difluoromethyl and trifluoromethyl; or

R^2 is pyrimidinyl, optionally substituted on 1 ring carbon atom by a substituent independently selected from the group consisting of C_{1-3} alkyl, difluoromethyl and trifluoromethyl; or

R^2 is phenyl optionally substituted on 1 or 2 ring carbon atoms by a substituent independently selected from the group consisting of halo, difluoromethyl, trifluoromethyl, methoxy and $-OCHF_2$; and

R^3 is hydrogen, C_{1-3} alkyl or chloro.

2. A compound of formula (I) or a pharmaceutically-acceptable adduct thereof, as claimed in claim 1, wherein:

R^1 is hydrogen, methyl or $-CH_2OMe$;

R^2 is pyridinyl, optionally substituted on 1 ring carbon atom by a substituent independently selected from the group consisting of methyl, difluoromethyl and trifluoromethyl; or

R^2 is pyrimidinyl, optionally substituted on 1 ring carbon atom by a substituent independently selected from the group consisting of methyl, difluoromethyl and trifluoromethyl; or
R^2 is phenyl optionally substituted on 1 or 2 ring carbon atoms by a substituent independently selected from the group consisting of fluoro, chloro, difluoromethyl, trifluoromethyl, methoxy and $-OCHF_2$; and
R^3 is hydrogen, methyl or chloro.

3. A compound of formula (I) or a pharmaceutically-acceptable adduct thereof, as claimed in claim 1, wherein:
R^1 is hydrogen, methyl or $-CH_2OMe$;
R^2 is pyridinyl, optionally substituted on 1 ring carbon atom by a substituent independently selected from the group consisting of methyl, difluoromethyl and trifluoromethyl; or
R^2 is pyrimidinyl, optionally substituted on 1 ring carbon atom by a trifluoromethyl; or
R^2 is phenyl optionally substituted on 1 or 2 ring carbon atoms by a substituent independently selected from the group consisting of fluoro, chloro, difluoromethyl and methoxy; and
R^3 is hydrogen, methyl or chloro.

4. A compound as claimed in claim 1, or a pharmaceutically-acceptable adduct thereof, wherein R^2 is 6-(difluoromethyl)pyridin-2-yl, 3-chlorophenyl, 3,4-difluorophenyl or 3,5-difluorophenyl.

5. A compound as claimed in claim 1, or a pharmaceutically-acceptable adduct thereof, wherein R^2 is 6-(difluoromethyl)pyridin-2-yl.

6. A compound as claimed in claim 1, or a pharmaceutically-acceptable adduct thereof, wherein R^2 is 3-chlorophenyl.

7. A compound as claimed in claim 1, or a pharmaceutically-acceptable adduct thereof, wherein R^2 is 3,4-difluorophenyl.

8. A compound as claimed in claim 1, or a pharmaceutically-acceptable adduct thereof, wherein R^2 is 3,5-difluorophenyl.

9. A compound as claimed in claim 1, or a pharmaceutically-acceptable adduct thereof, wherein said compound is;
(*S*)-7-(3-chlorobenzyl)-6-methyl-2-(2-((1-methyl-1*H*-pyrazol-5-yl)amino)pyrimidin-4-yl)-6,7-dihydroimidazo[1,2-a]pyrazin-8(5*H*)-one;
(*S*)-7-((6-(difluoromethyl)pyridin-2-yl)methyl)-6-methyl-2-(5-methyl-2-((1-methyl-1*H*-pyrazol-5-yl)amino)pyrimidin-4-yl)-6,7-dihydroimidazo[1,2-a]pyrazin-8(5*H*)-one;
(*R*)-7-(3,4-difluorobenzyl)-6-(methoxymethyl)-2-(5-methyl-2-((1-methyl-1*H*-pyrazol-5-yl)amino)pyrimidin-4-yl)-6,7-dihydroimidazo[1,2-a]pyrazin-8(5*H*)-one; or
(*S*)-7-(3,5-difluorobenzyl)-6-methyl-2-(5-methyl-2-((1-methyl-1*H*-pyrazol-5-yl)amino)pyrimidin-4-yl)-6,7-dihydroimidazo[1,2-a]pyrazin-8(5*H*)-one.

10. A compound as claimed in claim 1, or a pharmaceutically-acceptable adduct thereof, wherein said compound is
(*R*)-7-(3,4-Difluorobenzyl)-6-(methoxymethyl)-2-(5-methyl-2-((1-methyl-1*H*-pyrazol-5-yl)amino)pyrimidin-4-yl)-6,7-dihydroimidazo[1,2-a]pyrazin-8(5*H*)-one.

11. A pharmaceutically-acceptable adduct of a compound of formula (I) as claimed in claim 1, which is (*R*)-7-(3,4-Difluorobenzyl)-6-(methoxymethyl)-2-(5-methyl-2-((1-methyl-1*H*-pyrazol-5-yl)amino)pyrimidin-4-yl)-6,7-dihydroimidazo[1,2-a]pyrazin-8(5*H*)-one Ethanesulfonic acid salt.

12. A crystalline form of (*R*)-7-(3,4-Difluorobenzyl)-6-(methoxymethyl)-2-(5-methyl-2-((1-methyl-1*H*-pyrazol-5-yl)amino)pyrimidin-4-yl)-6,7-dihydroimidazo[1,2-a]pyrazin-8(5*H*)-one Ethanesulfonic acid salt as claimed in claim 12.

13. A pharmaceutically-acceptable adduct of a compound of formula (I) as claimed in claim 1, which is (*R*)-7-(3,4-Difluorobenzyl)-6-(methoxymethyl)-2-(5-methyl-2-((1-methyl-1*H*-pyrazol-5-yl)amino)pyrimidin-4-yl)-6,7-dihydroimidazo[1,2-a]pyrazin-8(5*H*)-one Adipic acid salt.

14. A crystalline form of (*R*)-7-(3,4-Difluorobenzyl)-6-(methoxymethyl)-2-(5-methyl-2-((1-methyl-1*H*-pyrazol-5-yl)amino)pyrimidin-4-yl)-6,7-dihydroimidazo[1,2-a]pyrazin-8(5*H*)-one Adipic acid salt as claimed in claim 14.

15. A compound as claimed in any of the preceding claims, or a pharmaceutically-acceptable adduct thereof, for use as a medicament.

16. A compound as claimed in any of claims 1 to 14, or a pharmaceutically-acceptable adduct thereof, for use in therapy.

17. A compound as claimed in any of claims 1 to 14, or a pharmaceutically-acceptable adduct thereof, for use in the prevention or treatment of cancer in a warm blooded animal such as man.

18. A compound of the Formula (I), or a pharmaceutically-acceptable adduct thereof, as claimed in any of claims 1 to 14 for use in the treatment of NSCLC, pancreatic or colo-rectal cancers.

19. Use of a compound as claimed in any of claims 1 to 14, or a pharmaceutically-acceptable adduct thereof, in the manufacture of a medicament for the prevention or treatment of cancer in a warm blooded animal such as man.

20. Use of compound of the Formula (I), or a pharmaceutically-acceptable adduct thereof, as claimed in any of claims 1 to 14 in the manufacture of a medicament for the treatment of NSCLC, pancreatic or colo-rectal cancers.

21. A pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically-acceptable adduct thereof, as claimed in claim 1, and a pharmaceutically-acceptable diluent or carrier.

22. A combination suitable for use in the treatment of cancer comprising a compound of Formula (I) or a pharmaceutically-acceptable adduct thereof, as claimed in claim 1, and another anti-tumour agent.

23. A combination as claimed in claim 22 comprising a compound of Formula (I) or a pharmaceutically-acceptable adduct thereof, as claimed in claim 1, and a MEK inhibitor.

24. A process for preparing a compound of formula (VI), said process comprising:

a) reaction of a compound of formula (VIII) with a compound of formula (XVI) in the presence of a suitable base in a suitable solvent, under conditions of ambient or elevated temperatures;



(VIII) (VI)

wherein R^1 and R^3 are defined for compound of formula (I) hereinbefore;

L^1 is a leaving group or a pre-cursor to a leaving group;

P^3 is a protecting group; and

R^4 is an alkyl group; and

b) optionally, an intermediate sulfamic acid is removed under conditions of aqueous acid in a suitable solvent; and

c) removal of the protecting group P^3 in the presence of a suitable acid in a suitable solvent, under ambient temperatures.